Build status - In Progress
Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 109
  • 372
  • 173
  • 13
  • 16
  • 343
  • 368
  • 4

Found 372 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
All genders
Phase 2
Interventional
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
 Technology for Detection of SARS-Cov-2 in HIV-Positive Cancer Patients
99 years or below
All genders
The main purpose of this study is to try a new type of laboratory test for COVID-19 (also called SARS-CoV-2 or novel coronavirus).  COVID-19 is a new disease, so not enough is known about it yet.  This study hopes to collect more information about who is most as risk from …
 Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
18 years - 99 years
All genders
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
 Testing novel drugs or drug combinations to treat breast cancer before surgery
18 years - 99 years
Female
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …
 TIME- Text-based intervention to minimize the time burden of routine cancer care
18 years - 99 years
All genders
The research study is being conducted to evaluate and test a text message-based strategy to streamline care. Our text message-based triage would screen patients before they come to the clinic, allowing patients with no side effects and normal bloodwork to get their infusion without having to wait. To ensure this …
18 years - 99 years
All genders
Phase 2
This study is being done to evaluate if participants with HER2-positive breast cancer who have no cancer remaining at surgery after 12 weeks of chemotherapy and two HER-targeting therapies eliminate further chemotherapy after surgery. Eligible subjects would be those with HER2-positive breast cancer.
 REVITALIZE: A Telehealth Intervention for Women with Advanced Ovarian Cancer and Inhibitor-Related Fatigue
18 years - 99 years
Female
Interventional
In this study, we are comparing the use of two different interventions, 1) a 6 week skills-based telehealth intervention that provides participants with support, knowledge, and skills for coping with fatigue, or 2) educational materials and resources, to help you manage your fatigue.
 Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA)
18 years - 99 years
All genders
Phase 3
Interventional
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies.
99 years or below
All genders
Phase 1
Women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 30 evaluable subjects who have been recommended to start systemic therapy as part of …
 Clinical trial of TC-210 T CELLS in Patients with Advanced Mesothelin Expressing Cancer
99 years or below
All genders
Phase 1
Your partner is participating in a research study which is looking to determine the safety and efficacy of the drug product, TC-210 T Cells. Your partner has received theTC-210 T Cells. You are being asked to provide information to the Sponsor and your partner’s study doctor, because your partner has …
271 - 280 of 372